Redx Pharma CEO reports “good progress across the board”

Category: Cloud PRWire 0

Sharing is caring!

–News Direct–

Redx Pharma PLC (AIM:REDX) CEO Lisa Anson speaks to Thomas Warner from Proactive after the clinical-stage biotechnology company released its final audited results for the year to 30 September.

Anson discusses the company's performance in 2023 and outlined its plans for 2024. She highlights the successful launch of a Phase 2 program for lead asset Zelasudil, aimed at treating idiopathic pulmonary fibrosis, a challenging lung condition. Additionally, Anson touches upon another promising asset targeting the same mechanism, which is poised to enter clinical trials next year following extensive preclinical work.

On the financial front, despite a challenging year, Redx Pharma successfully raised 14.1 million, ensuring funding through September 2024. This financial stability is crucial for achieving key milestones, which Anson believes will be pivotal for the company's growth. Looking ahead to 2024, Anson anticipates significant developments, including the release of Phase 2 data in idiopathic pulmonary fibrosis and resolving FDA regulatory issues in the first half of the year.

Moreover, the company aims to initiate a Phase 1 study for its RXC008 (ROCK) asset, which would ne the sixth time Redx Pharma has brought a drug into clinical trials. In addition to these advances, Redx Pharma is also focusing on kidney fibrosis and oncology programs, with plans to progress these into clinical stages by 2026.

Anson also emphasises the potential for new partnerships, particularly in advancing their oncology program for GI cancers, highlighting Redx Pharma's strategic approach to collaboration and development.

This interview underlines Redx Pharma's significant strides in 2023 and sets a promising outlook for 2024, positioning the company as a key player in the pharmaceutical industry.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

View source version on

Redx Pharma PLC

comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Emerald Journal journalist was involved in the writing and production of this article.

Related Articles